These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 32654663)

  • 1. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study.
    Emrich IE; Lizzi F; Siegel JD; Seiler-Mussler S; Ukena C; Kaddu-Mulindwa D; D'Amelio R; Wagenpfeil S; Brandenburg VM; Böhm M; Fliser D; Heine GH
    BMC Med; 2020 Jul; 18(1):178. PubMed ID: 32654663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The differential effect of modern intravenous iron on fibroblast growth factor 23 and phosphate in non-dialysis dependent CKD - the exploratory randomized controlled double-blind ExplorIRON-CKD study.
    Kassianides X; Bhandari S
    BMC Nephrol; 2024 Feb; 25(1):54. PubMed ID: 38347520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England.
    Iqbal TH; Kennedy N; Dhar A; Ahmed W; Pollock RF
    J Med Econ; 2024; 27(1):392-403. PubMed ID: 38391240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
    JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.
    Schaefer B; Zoller H; Wolf M
    J Clin Endocrinol Metab; 2022 Mar; 107(4):1009-1019. PubMed ID: 34850000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency.
    Frazier R; Hodakowski A; Cai X; Lee J; Zakarija A; Stein B; David V; Wolf M; Isakova T; Mehta R
    Bone; 2020 Dec; 141():115559. PubMed ID: 32730929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    World J Gastroenterol; 2021 May; 27(17):2039-2053. PubMed ID: 34007138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.
    Schaefer B; Würtinger P; Finkenstedt A; Braithwaite V; Viveiros A; Effenberger M; Sulzbacher I; Moschen A; Griesmacher A; Tilg H; Vogel W; Zoller H
    PLoS One; 2016; 11(12):e0167146. PubMed ID: 27907058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Risk of Hypophosphatemia in Patients with Previous Bariatric Surgery Receiving Ferric Carboxymaltose: A Prospective Cohort Study.
    Schoeb M; Räss A; Frei N; Aczél S; Brändle M; Bilz S
    Obes Surg; 2020 Jul; 30(7):2659-2666. PubMed ID: 32221822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
    Zoller H; Wolf M; Blumenstein I; Primas C; Lindgren S; Thomsen LL; Reinisch W; Iqbal T
    Gut; 2023 Apr; 72(4):644-653. PubMed ID: 36343979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose.
    Pollock RF; Kalra PA; Kalra PR; Ahmed FZ
    Adv Ther; 2022 Oct; 39(10):4678-4691. PubMed ID: 35947351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia.
    Pollock RF; Biggar P
    Expert Rev Hematol; 2020 Feb; 13(2):187-195. PubMed ID: 31928094
    [No Abstract]   [Full Text] [Related]  

  • 14. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
    Cococcioni L; Pensabene L; El-Khouly S; Chadokufa S; McCartney S; Saliakellis E; Kiparissi F; Borrelli O
    Dig Liver Dis; 2021 Jul; 53(7):830-834. PubMed ID: 33775573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.
    Schaefer B; Tobiasch M; Viveiros A; Tilg H; Kennedy NA; Wolf M; Zoller H
    Br J Clin Pharmacol; 2021 May; 87(5):2256-2273. PubMed ID: 33188534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: A systematic review and meta-analysis.
    Shin HW; Go DY; Lee SW; Choi YJ; Ko EJ; You HS; Jang YK
    Medicine (Baltimore); 2021 May; 100(20):e24571. PubMed ID: 34011020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Ferric Carboxymaltose in Chinese Patients with Iron-deficiency Anemia.
    Ding Y; Zhu X; Li X; Zhang H; Wu M; Liu J; Palmen M; Roubert B; Li C
    Clin Ther; 2020 Feb; 42(2):276-285. PubMed ID: 31937462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
    Filippatos G; Ponikowski P; Farmakis D; Anker SD; Butler J; Fabien V; Kirwan BA; Macdougall IC; Metra M; Rosano G; Ruschitzka F; van der Meer P; Wächter S; Jankowska EA;
    Circulation; 2023 May; 147(22):1640-1653. PubMed ID: 37051919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases.
    Laass MW; Straub S; Chainey S; Virgin G; Cushway T
    BMC Gastroenterol; 2014 Oct; 14():184. PubMed ID: 25326048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.